Impact of current antiretroviral therapies on neuroAIDS

References

• Mocroft A, Ledergerber B, Katlama C et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet362, 22–29 (2003).
   PubMed Web of Science ®Google Scholar
• McArthur JC, Hoover DR, Bacellar H et al. Dementia in AIDS patients: incidence and risk factors. Multicenter AIDS Cohort Study. Neurology43, 2245–2252 (1993).
   PubMed Web of Science ®Google Scholar
• So YT, Holtzman DM, Abrams DI, Olney RK. Peripheral neuropathy associated with acquired immunodeficiency syndrome. Prevalence and clinical features from a population-based survey. Arch. Neurol.45, 945–948 (1988).
   PubMed Web of Science ®Google Scholar
• Vivithanaporn P, Heo G, Gamble J et al. Neurologic disease burden in treated HIV/AIDS predicts survival: a population-based study. Neurology75, 1150–1158 (2010).
   PubMed Web of Science ®Google Scholar
• Jones G, Power C. Regulation of neural cell survival by HIV-1 infection. Neurobiol. Dis.21, 1–17 (2006).
   PubMed Web of Science ®Google Scholar
• Dore GJ, Correll PK, Li Y et al. Changes to AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS13, 1249–1253 (1999).
   PubMed Web of Science ®Google Scholar
• Ives NJ, Gazzard BG, Easterbrook PJ. The changing pattern of AIDS-defining illnesses with the introduction of highly active antiretroviral therapy (HAART) in a London clinic. J. Infect.42, 134–139 (2001).
   PubMed Web of Science ®Google Scholar
• Portegies P, de Gans J, Lange JM et al. Declining incidence of AIDS dementia complex after introduction of zidovudine treatment. Br. Med. J.299, 819–821 (1989).
   PubMed Web of Science ®Google Scholar
• Capparelli EV, Letendre SL, Ellis RJ et al. Population pharmacokinetics of abacavir in plasma and cerebrospinal fluid. Antimicrob. Agents Chemother.49, 2504–2506 (2005).
   PubMed Web of Science ®Google Scholar
• Anthonypillai C, Gibbs JE, Thomas SA. The distribution of the anti-HIV drug, tenofovir (PMPA), into the brain, CSF and choroid plexuses. Cerebrospinal Fluid Res.3, 1 (2006).
   PubMedGoogle Scholar
• von Giesen HJ, Koller H, Theisen A, Arendt G. Therapeutic effects of nonnucleoside reverse transcriptase inhibitors on the central nervous system in HIV-1-infected patients. J. Acquir. Immune Defic. Syndr.29, 363–367 (2002).
   PubMed Web of Science ®Google Scholar
• Best BM, Koopmans PP, Letendre SL et al. Efavirenz concentrations in CSF exceed IC50 for wild-type HIV. J. Antimicrob. Chemother.66(2), 354–357 (2010).
   PubMed Web of Science ®Google Scholar
• Taylor S, Pereira A. Penetration of HIV-1 protease inhibitors into CSF and semen. HIV Med.1(Suppl. 2), 18–22 (2000).
   PubMedGoogle Scholar
• Capparelli EV, Holland D, Okamoto C et al. Lopinavir concentrations in cerebrospinal fluid exceed the 50% inhibitory concentration for HIV. AIDS19, 949–952 (2005).
   PubMed Web of Science ®Google Scholar
• Yilmaz A, Izadkhashti A, Price RW et al. Darunavir concentrations in cerebrospinal fluid and blood in HIV-1-infected individuals. AIDS Res. Hum. Retroviruses25, 457–461 (2009).
   PubMed Web of Science ®Google Scholar
• Yilmaz A, Stahle L, Hagberg L et al. Cerebrospinal fluid and plasma HIV-1 RNA levels and lopinavir concentrations following lopinavir/ritonavir regimen. Scand. J. Infect. Dis.36, 823–828 (2004).
   PubMed Web of Science ®Google Scholar
• Antinori A, Giancola ML, Grisetti S et al. Factors influencing virological response to antiretroviral drugs in cerebrospinal fluid of advanced HIV-1-infected patients. AIDS16, 1867–1876 (2002).
   PubMed Web of Science ®Google Scholar
• Cysique LA, Maruff P, Brew BJ. Antiretroviral therapy in HIV infection: are neurologically active drugs important? Arch. Neurol.61, 1699–1704 (2004).
   PubMedGoogle Scholar
• Cysique LA, Maruff P, Brew BJ. Variable benefit in neuropsychological function in HIV-infected HAART-treated patients. Neurology66, 1447–1450 (2006).
   PubMed Web of Science ®Google Scholar
• Sacktor N, Tarwater PM, Skolasky RL et al. CSF antiretroviral drug penetrance and the treatment of HIV-associated psychomotor slowing. Neurology57, 542–544 (2001).
   PubMedGoogle Scholar
• Evers S, Rahmann A, Schwaag S et al. Prevention of AIDS dementia by HAART does not depend on cerebrospinal fluid drug penetrance. AIDS Res. Hum. Retroviruses20, 483–491 (2004).
   PubMedGoogle Scholar
• Giancola ML, Lorenzini P, Balestra P et al. Neuroactive antiretroviral drugs do not influence neurocognitive performance in less advanced HIV-infected patients responding to highly active antiretroviral therapy. J. Acquir. Immune Defic. Syndr.41, 332–337 (2006).
   PubMed Web of Science ®Google Scholar
• Letendre S, Marquie-Beck J, Capparelli E et al. Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch. Neurol.65, 65–70 (2008).
   PubMed Web of Science ®Google Scholar
• Letendre SL, Ellis RJ, Ances BM, McCutchan JA. Neurologic complications of HIV disease and their treatment. Top. HIV Med.18, 45–55 (2010).
   PubMedGoogle Scholar
• Canestri A, Lescure FX, Jaureguiberry S et al. Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy. Clin. Infect. Dis.50, 773–778 (2010).
   PubMed Web of Science ®Google Scholar
• Tozzi V, Balestra P, Salvatori MF et al. Changes in cognition during antiretroviral therapy: comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders. J. Acquir. Immune Defic. Syndr.52, 56–63 (2009).
   PubMed Web of Science ®Google Scholar
• Marra CM, Zhao Y, Clifford DB et al. Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS23, 1359–1366 (2009).
   PubMed Web of Science ®Google Scholar
• Yilmaz A, Verhofstede C, D’Avolio A et al. Treatment intensification has no effect on the HIV-1 central nervous system infection in patients on suppressive antiretroviral therapy. J. Acquir. Immune Defic. Syndr. DOI: 10.1097/QAI.0b013e3181f5b3d1 (2010) (Epub ahead of print).
   PubMedGoogle Scholar
• Garvey L, Winston A, Sabin C. Do antiretroviral combination therapies with greater central nervous system (CNS) penetration prevent the development of CNS opportunistic diseases? Presented at: Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, USA, 16–19 February 2010.
   Google Scholar
• Berger JR, Avison M. The blood brain barrier in HIV infection. Front. Biosci.9, 2680–2685 (2004).
   PubMed Web of Science ®Google Scholar
• Power C, Kong PA, Crawford TO et al. Cerebral white matter changes in acquired immunodeficiency syndrome dementia: alterations of the blood–brain barrier. Ann. Neurol.34, 339–350 (1993).
   PubMed Web of Science ®Google Scholar
• Luciano CA, Pardo CA, McArthur JC. Recent developments in the HIV neuropathies. Curr. Opin. Neurol.16, 403–409 (2003).
   PubMed Web of Science ®Google Scholar
• Keswani SC, Chander B, Hasan C et al. FK506 is neuroprotective in a model of antiretroviral toxic neuropathy. Ann. Neurol.53, 57–64 (2003).
   PubMed Web of Science ®Google Scholar
• Pettersen JA, Jones G, Worthington C et al. Sensory neuropathy in human immunodeficiency virus/acquired immunodeficiency syndrome patients: protease inhibitor-mediated neurotoxicity. Ann. Neurol.59, 816–824 (2006).
   PubMed Web of Science ®Google Scholar
• Ellis RJ, Marquie-Beck J, Delaney P et al. Human immunodeficiency virus protease inhibitors and risk for peripheral neuropathy. Ann. Neurol.64, 566–572 (2008).
   PubMedGoogle Scholar
• Maggiolo F. Efavirenz: a decade of clinical experience in the treatment of HIV. J. Antimicrob. Chemother.64, 910–928 (2009).
   PubMed Web of Science ®Google Scholar
• Wise ME, Mistry K, Reid S. Drug points: neuropsychiatric complications of nevirapine treatment. Br. Med. J.324, 879 (2002).
   PubMedGoogle Scholar
• Allavena C, Le Moal G, Michau C, Chiffoleau A, Raffi F. Neuropsychiatric adverse events after switching from an antiretroviral regimen containing efavirenz without tenofovir to an efavirenz regimen containing tenofovir: a report of nine cases. Antivir. Ther.11, 263–265 (2006).
   PubMed Web of Science ®Google Scholar
• Pistell PJ, Gupta S, Knight AG et al. Metabolic and neurologic consequences of chronic lopinavir/ritonavir administration to C57BL/6 mice. Antiviral Res.88, 334–342 (2010).
   PubMedGoogle Scholar
• Romao PR, Lemos JC, Moreira J et al. Anti-HIV drugs nevirapine and efavirenz affect anxiety-related behavior and cognitive performance in mice. Neurotox. Res.19(1), 73–80 (2011).
   PubMed Web of Science ®Google Scholar
• Robertson KR, Su Z, Margolis DM et al. Neurocognitive effects of treatment interruption in stable HIV-positive patients in an observational cohort. Neurology74, 1260–1266 (2010).
   PubMed Web of Science ®Google Scholar
• Liner J, Meeker R, Robertson K. CNS toxicity of antiretroviral drugs. Presented at: Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, USA, 16–19 February 2010.
   Google Scholar
• Cysique LA, Maruff P, Brew BJ. Prevalence and pattern of neuropsychological impairment in human immunodeficiency virus-infected/acquired immunodeficiency syndrome (HIV/AIDS) patients across pre- and post-highly active antiretroviral therapy eras: a combined study of two cohorts. J. Neurovirol.10, 350–357 (2004).
   PubMed Web of Science ®Google Scholar
• Sterne JA, May M, Costagliola D et al. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet373, 1352–1363 (2009).
   PubMed Web of Science ®Google Scholar
• Kmonickova E, Potmesil P, Holy A, Zidek Z. Purine P1 receptor-dependent immunostimulatory effects of antiviral acyclic analogues of adenine and 2,6-diaminopurine. Eur. J. Pharmacol.530, 179–187 (2006).
   PubMedGoogle Scholar
• Lagathu C, Eustace B, Prot M et al. Some HIV antiretrovirals increase oxidative stress and alter chemokine, cytokine or adiponectin production in human adipocytes and macrophages. Antivir. Ther.12, 489–500 (2007).
   PubMed Web of Science ®Google Scholar